NPRL3 and epilepsy: Clinical laboratories performing hemoglobinopathy testing or chromosomal microarrays should consider including the information about this overlap in their reporting if such deletions are detected, for the ordering clinicians to consider either diagnosis, keeping in mind that NPRL3-related epilepsy has decreased penetrance.